[Statins and probiotics in the prevention of urologic diseases]
- PMID: 17458532
- DOI: 10.1007/s00120-007-1341-6
[Statins and probiotics in the prevention of urologic diseases]
Abstract
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, better known as statins, may be associated with reduced prostate cancer risk. Statins have been reported to demonstrate chemopreventive potentials in prostate cancer cell lines, but the association in observational studies has been inconclusive.Probiotics, defined as live microbial food supplements, have been tested for an impact on a variety of clinical conditions, e.g., urinary tract infections and calcium oxalate stone disease. Furthermore, oral administration of a lactic acid bacterium was effective against experimentally induced bladder tumors. Relationships between cancer and intake of probiotics have mainly been studied in bladder and colon cancer.
Similar articles
-
Statins and prostate cancer: molecular and clinical aspects.Eur J Cancer. 2011 Apr;47(6):819-30. doi: 10.1016/j.ejca.2011.01.005. Epub 2011 Feb 25. Eur J Cancer. 2011. PMID: 21354784 Review.
-
Atorvastatin: a potential chemopreventive agent in bladder cancer.Urology. 2005 Dec;66(6):1209-12. doi: 10.1016/j.urology.2005.06.075. Urology. 2005. PMID: 16360444
-
The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditions.Urol Clin North Am. 2004 May;31(2):213-8. doi: 10.1016/j.ucl.2004.01.009. Urol Clin North Am. 2004. PMID: 15123401 Review.
-
Review of recent evidence in support of a role for statins in the prevention of prostate cancer.Curr Opin Urol. 2008 May;18(3):333-9. doi: 10.1097/MOU.0b013e3282f9b3cc. Curr Opin Urol. 2008. PMID: 18382245 Review.
-
Statins and prostate cancer risk: a case-control study.Am J Epidemiol. 2005 Aug 15;162(4):318-25. doi: 10.1093/aje/kwi203. Epub 2005 Jul 13. Am J Epidemiol. 2005. PMID: 16014776
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical